Relypsa Inc.
This article was originally published in Start Up
Executive Summary
When Amgen bought Ilypsa last summer, it kept one of its non-absorbed polymer drug candidates for itself, leaving Ilypsa's other candidates in limbo. Key Ilypsa employees and investors wanted to carry out those programs, and with Amgen's blessing, they moved swiftly to form Relypsa Inc., which retains rights to Ilypsa's remaining pipeline and drug discovery platform. Relypsa management, all from Ilypsa, intends to continue Ilypsa's fast pace of pipeline development, with a NCE planned for entry into the clinic every year for the next three years.